GENERIC NAME

(BRAND NAME)

CLASSIFICATION

INDICATIONS Vertigo/Meniere 's disease Vertiginous syndromes, other disorders of vestibular system Hypotension Ventricular Fibrillation (Cardiac Arrest) & Unstable Ventricular Tachycardia

SIDE EFFECTS Headache. Upset stomach / Dyspepsia Insomnia Nausea fatigue, eye deposits, tremor, unsteady gait, nausea, vomiting, constipation, weight loss, dizziness, visual changes constipation heartburn dizziness headache

NURSING RESPONSIBILITIES 1. Avoid contact of oral solution or injection with skin 2. Raise bed rails 3. Safety measures 4. Supervise ambulation 1. Monitor ECG, HR, BP 2. Use a 0.22 micron filter 3. Use glass bottle for continuous infusion. A bag may be used for the bolus as long as it is given within one hour of mixing. 1. Closely monitor BP during first 2weeks of drug therapy or when dosage is adjusted esp. in patients with heart failure and hyponatremia. 2. Be alert for s/sx of angioedema. 3. Assess patient for bradycardia and hypotension w/c may indicate AV block. 4. Take the drug with food. 5. Encourage patient to increase dietary fiber intake to prevent constipation. 1.Monitor vital signs , and ECG during infusion, 2. Watch for dsyarrythmias and ischemia also monitor, PCWP,CVP, CO2, and urinary output

Betahistine HCL (Serc)

Antivertigo

Amiodarone (Cordarone)

Antiarrhythmic Agent

Verapamil (Calan)

Anti-Anginal Drugs Calcium Antagonists

Angina pectoris Hypertension AF and tachycardias to bring down HR Mania and Hypomania Migraine and cluster headaches

Dopamine (Intropin)

Adrenergic and Dopaminergic Cardiac Stimulants Sympathomime tic

Acute heart failure Hypotension Low cardiac output states

Nausea and vomiting Heartburn Sedation/ Daytime sleepiness Leg swelling

Dizziness Impulsive or compulsive behaviors e.g gambling, overeating, hypersexualit y problems

3.Monitor for possible adverse reaction 4. Assess for heart failure: dsypnea ,neck vein distention, 5. Assess for oxygenation and perfusion deficit.